Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 8/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813158 | 0.90 | CHEK1 (0.40) | PRKDCCHEK1DGAT1NSD2 | |
| SCHEMBL4823912 | 0.82 | TDP1 (0.34) | PRKDCCHEK1DGAT1 | |
| SCHEMBL4813990 | 0.82 | CHEK1 (0.48) | CHEK1 | |
| SCHEMBL4817374 | 0.73 | CHEK1 (0.54) | CHEK1 | |
| SCHEMBL4806272 | 0.72 | CHEK1 (0.52) | CHEK1 | |
| SCHEMBL4814292 | 0.72 | CHEK1 (0.44) | CHEK1 | |
| SCHEMBL4814974 | 0.72 | CHEK1 (0.44) | PRKDCCHEK1DGAT1 | |
| SCHEMBL4813077 | 0.70 | CHEK1 (0.75) | CHEK1 | |
| SCHEMBL15312108 | 0.68 | DGAT1 (0.35) | CHEK1DGAT1 | |
| SCHEMBL4817734 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | PRKDC 38/4885CHEK1 73/4885DGAT1 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.